Jefferies London 2026: Protagonist Therapeutics' CEO Dinesh Patel discusses the launch of ICOTYDE, and the company's pipeline, which is well funded now due to commercial success
He comments on the early days of JNJ's ICOTYDE launch, developing an optimized IL-17, the obesity space, and more.
Coverage brought to you by










.png)
